Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4901
Abstract: The diagnosis of central nervous system metastases in patients with radioiodine refractory differentiated thyroid cancer is a late and rare event that occurs in less than 1% of patients. Definitive conclusions on the overall clinical… read more here.
Keywords: central nervous; patients radioiodine; radioiodine refractory; treatment ... See more keywords
Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5127
Abstract: Antiangiogenic tyrosine kinase inhibitors are the treatment of choice in radioiodine refractory‐differentiated thyroid cancer (RR‐DTC). Nevertheless, these therapies present class toxicities that may impact their feasibility and patient's quality of life. Their mechanism of action… read more here.
Keywords: refractory differentiated; differentiated thyroid; thyroid cancer; radioiodine refractory ... See more keywords
Radioiodine refractory differentiated thyroid cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2018.03.012
Abstract: Differentiated thyroid cancer (DTC) is usually curable with surgery, radioactive iodine (RAI), and thyroid-stimulating hormone (TSH) suppression. However, local recurrence and/or distant metastases occur in approximately 15% of cases during follow-up, and nearly two-thirds of… read more here.
Keywords: dtc; refractory differentiated; differentiated thyroid; thyroid cancer ... See more keywords
Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2102000
Abstract: ABSTRACT Objectives Radioiodine-refractory differentiated thyroid cancer (RAI-rDTC) has frequently been associated with poor prognosis. We conducted a meta-analysis of published randomized controlled trials to evaluate multi-kinase inhibitors’ efficacy and safety profile treatment. Methods A comprehensive… read more here.
Keywords: refractory differentiated; meta analysis; differentiated thyroid; thyroid cancer ... See more keywords
177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000002219
Abstract: Introduction Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by… read more here.
Keywords: refractory differentiated; 177lu dotatate; differentiated thyroid; dotatate ... See more keywords
Reply: Clinical efficacy of lenvatinib for the treatment of radioiodine‐refractory thyroid carcinoma: A systematic review and meta‐analysis of clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Endocrinology"
DOI: 10.1111/cen.14718
Abstract: Dear Editor, we read with great interest the paper by Zhipeng et al, sharing the perspective that lenvatinib is beneficial for the treatment of radioiodine-refractory thyroid cancer in terms of the extension of progression-free survival… read more here.
Keywords: radioiodine refractory; treatment radioiodine; refractory thyroid;
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-0437
Abstract: Abstract Purpose: Restoration of iodine incorporation (redifferentiation) by MAPK inhibition was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma (RR-TC). However, results were unsatisfactory in BRAFV600E-mutant (BRAF-MUT) RR-TC. Here we assess safety and efficacy of redifferentiation… read more here.
Keywords: arm; redifferentiation; braf; radioiodine refractory ... See more keywords
An exploratory phase II clinical trial of apatinib in progressive radioiodine refractory differentiated thyroid cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e18094
Abstract: e18094Background: Anti-angiogenic TKI is the most potential effective strategy for patients (pts) with progressive radioiodine refractory differentiated thyroid cancer (RAIR-DTC). This phase II tri... read more here.
Keywords: progressive radioiodine; refractory differentiated; differentiated thyroid; thyroid cancer ... See more keywords
Radiomics-based prediction of response to multikinase inhibitors in radioiodine-refractory differentiated thyroid cancer patients.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.6077
Abstract: 6077 Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) represent the first-line treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC). Currently, no predictive factors for the activity of these drugs are available. We investigated whether radiomics may have… read more here.
Keywords: response; refractory differentiated; response tkis; differentiated thyroid ... See more keywords
Redifferentiation of radioiodine-refractory thyroid cancers.
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine-related cancer"
DOI: 10.1530/erc-19-0491
Abstract: The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to primary or acquired resistance or the necessity of drug… read more here.
Keywords: refractory thyroid; radioiodine refractory; thyroid cancers;
Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "European thyroid journal"
DOI: 10.1530/etj-21-0065
Abstract: OBJECTIVE Sorafenib and lenvatinib have been recommended as standard tyrosine kinase inhibitors (TKIs) for progressive radioiodine-refractory differentiated thyroid carcinoma (RR-DTC). However, their efficacy remains limited with unresolved drug resistance. Therefore, we conceived this open-label study… read more here.
Keywords: dtc; treatment; salvage treatment; apatinib ... See more keywords